



Robert Greene Sterne Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Robert E. Sokohl Michael O. Lee Steven R. Ludwig John M. Covert Linda E. Homer Robert C. Millonio Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim

Patrick E. Garrett Jeffrey T. Helvey Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian I Del Buono Edward W. Yee Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Daniel A. Klein Michael D. Specht

July 20, 2006

Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Matthew E. Kelley Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Young Tang

Christopher J. Walsh W. Blake Coblentz* James J. Pohl John T. Haran Mark W. Rygiel Kevin W. McCabe

Registered Patent Agents Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Mita Mukherjee

Art Unit To Be Assigned

Attn: Mail Stop Amendment

Scott M. Woodhous Liliana Di Nola-Baror Peter A. Socarras Jeffrey K. Mills Danielle I Letting Lori Brandes Steven C. Oppenheime

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland · Admitted only in Virginia Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8660 INTERNET ADDRESS: TDURKIN@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/578,770; Filed: May 9, 2006

Method of Concentrating and Purifying Nucleic Acid and Apparatus For:

Therefor

Inventors: HASHIGUCHI et al. Our Ref:

0666.2880000/TGD/AFK

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement;
- 2. First Supplemental Information Disclosure Statement PTO Form SB/08A citing one (1) reference (US1);
- 3. First Supplemental Information Disclosure Statement PTO Form SB/08B citing one (1) reference (NPL2);
- 4. A copy of cited document NPL2; and
- 5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.L.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skqf.com

Commissioner for Patents July 20, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Tracy-Gene G. Durkin Attorney for Applicants Registration No. 32,831

TGD/AFK/k-b Enclosures

556740v1



In re application of:

HASHIGUCHI et al.

Appl. No.: 10/578,770

Filed: May 9, 2006

For: Method of Concentrating and Purifying Nucleic Acid and

Apparatus Therefor

Confirmation No.: To Be Assigned

Art Unit: To Be Assigned Examiner: To Be Assigned

Atty. Docket: 0666.2880000/TGD/AFK

First Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have checked the appropriate boxes below.

- □ 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 3. Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

□ a.	Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each
	item of information contained in this Information Disclosure
	Statement was first cited in any communication from a foreign
	patent office in a counterpart foreign application not more than
	three months prior to the filing of this Information Disclosure
	Statement. 37 C.F.R. § 1.97(e)(1).
□ b.	Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item
	of information in this Information Disclosure Statement was cited
	in a communication from a foreign patent office in a counterpart
	foreign application and, to my knowledge after making reasonable
	inquiry, was known to any individual designated in 37 C.F.R.
	§ 1.56(c) more than three months prior to the filing of this
	Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
☐ c.	Attached is our PTO-2038 Credit Card Payment Form in the
	amount of \$ in payment of the fee under 37 C.F.R. §
	1.17(p).
Filing under 3	7 C.F.R. § 1.97(d) This Information Disclosure Statement is being
filed more tha	n three months after the U.S. filing date and after the mailing date
of a Final Reje	ection or Notice of Allowance, but before payment of the Issue Fee.
Enclosed find	our PTO-2038 Credit Card Payment Form in the amount of

\$_____ in payment of the fee under 37 C.F.R. § 1.17(p); in addition:

4. Filing

- a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
- b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- ☐ 5. The document(s) was/were cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38.
- 6. A concise explanation of the relevance of the non-English language document(s) appears below in accordance with 37 C.F.R. § 1.98(a)(3).

document was not available to Applicants at that time. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited on the attached IDS Forms are submitted.

□ 8.	Copies of the documents were cited by or submitted to the Office in an IDS that
	complies with 37 C.F.R. § 1.98(a)-(c) in Application No, filed
	, which is relied upon for an earlier filing date under 35 U.S.C.
	§ 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).
 9.	It is expected that the examiner will review the prosecution and cited art in the
	parent application no(s) in accordance with MPEP 2001.06(b), and
	indicate in the next communication from the office that the art cited in the earlier
	prosecution history has been reviewed in connection with the present application.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Tracy-Gene G. Durkin Attorney for Applicants Registration No. 32,831

Date: July 20, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

553372v1

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if	
DIDOT CHIDDI DAMBATTAT	Application Number	
FIRST SUPPLEMENTAL	Filing Date	
INFORMATION DISCLOSURE	First Named Inventor	
STATEMENT BY APPLICANT	Art Unit	
(III		-

Complete if Known				
Application Number	10/578,770			
Filing Date	May 9, 2006			
First Named Inventor	Satoshi HASHIGUCHI			
Art Unit	To Be Assigned			
Examiner Name	To Be Assigned			
Attorney Docket Number	0666.2880000/TGD/AFK			

			U.S. PATENT DO	OCUMENTS		
Examiner	Cite No.'	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*		No.¹ Number-Kind Code² (If Known) MM-DD	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
	US1	2006-0134620	06-22-2006	Hirai et al.		
	US2					
	US3					
	US4					
	US5					
	US6					
	US7					
	US8					
	US9				_	
	US10					
•	US11				_	
	US12					
	US13					
	US14					
	US15					
	US16					
	US17					
	US18					
	US19					
	US20					

		Fo	REIGN PATENT DO	CUMENTS	···	
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
	FP1					
	FP2					
	FP3					
	FP4					
	FP5					
	FP6					
	FP7					
	FP8					
	FP9					

556708v1

Sheet

of

1

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			AT	Application Number	10/578,770	
				Filing Date	May 9, 2006	
				First Named Inventor	Satoshi HASHIGUCHI	
				Art Unit	To Be Assigned	
(Use as many sheets as necessary)		Examiner Name	To Be Assigned			
Sheet	1	of	1	Attorney Docket Number	0666.2880000/TGD/AFK	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²			
	NPL1					
	NPL2	Edited by the Japanese Biochemical Society, Tanpakushitsu I, Bunri Seito Seishitsu, first edition, Tokyo Kagaku Dojin, February 26, 1990, pages 53-66.				
	NPL3					
	NPL4					
_	NPL5					
	NPL6					
	NPL7					
	NPL8					
	NPL9					
	NPL10					

556706v1

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.